Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. März 2020 07:00 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

– Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provide further support for continued development – – Solid continues to make progress to...
09. Januar 2020 08:00 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing...
18. Dezember 2019 06:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Provides Data Update from SGT-001 Development Program

- Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne - Previously...
12. November 2019 06:45 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Provides SGT-001 Program Update

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA)...
02. Oktober 2019 07:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question...
05. September 2019 07:30 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders¹ that summarizes...
14. August 2019 07:25 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update

– Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial – – Study protocol amended to expedite clinical execution of SGT-001 – – Recent $60M capital raise extends...
26. Juli 2019 07:25 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors

CAMBRIDGE, Mass., July 26, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of...
13. Mai 2019 16:10 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update

– Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg – – Clinical activities underway at additional study sites – CAMBRIDGE, Mass., May 13,...
15. April 2019 16:01 ET | Quelle: Solid Biosciences Inc.

Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD)...

Vorherige Seite